Advertisement
Advertisement
MIRM
Mirum Pharmaceuticals, Inc. Common Stock
87.87
USDSponsored
-5.17
-5.56%
Mar 05, 16:00 UTC -5
Closed
After-Market
88.50
+0.63
+0.71%
MIRM Earnings Reports
Positive Surprise Ratio
MIRM beat 13 of 27 last estimates.
48%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$150.71M
/-$0.13
Implied change from Q4 25 (Revenue/ EPS)
+1.19%
/+30.00%
Implied change from Q1 25 (Revenue/ EPS)
+35.06%
/-56.67%
Mirum Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 25, 2026, MIRM reported earnings of -0.10 USD per share (EPS) for Q4 25, missing the estimate of 0.04 USD, resulting in a -330.95% surprise. Revenue reached 148.93 million, compared to an expected 144.64 million, with a 2.97% difference. The market reacted with a +1.05% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 150.71 million USD, implying an increase of 30.00% EPS, and increase of 1.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
Keros Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.86
Surprise
-34.10%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Mirum Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Mirum Pharmaceuticals, Inc. Common Stock reported EPS of -$0.10, missing estimates by -330.95%, and revenue of $148.93M, 2.97% above expectations.
How did the market react to Mirum Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 1.05%, changed from $89.50 before the earnings release to $90.44 the day after.
When is Mirum Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Mirum Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 10
analysts, Mirum Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $150.71M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement